...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines
【24h】

Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines

机译:发现高效微管蛋白聚合抑制剂:新型2,7-二芳基-1,2,4]三唑唑的设计,合成和结构 - 活性关系[1,5-A]嘧啶

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Y By removing 5-methyl and 6-acetyl groups in our previously reported compound 3, we designed a series of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidine derivatives as potential tubulin polymerization inhibitors. Among them, compound 5e displayed low nanomolar antiproliferative efficacy on HeLa cells which was 166-fold higher than the lead analogue 3. Interestingly, 5e displayed significant selectivity in inhibiting cancer cells over HEK-293 (normal human embryonic kidney cells). In addition, 5e dose-dependently arrested HeLa in G2/M phase through the alterations of the expression levels of p-cdc2 and cyclin B1, and caused HeLa cells apoptosis by regulation of expressions of cleaved PARP. Further evidence demonstrated that 5e effectively inhibited tubulin polymerization and was 3-fold more powerful than positive control CA-4. Moreover, molecular docking analysis indicated that 5e overlapped well with CA-4 in the colchicine-binding site. These studies demonstrated that 2,7-diaryl-[1,2,4]triazolo [1,5-a]pyrimidine skeleton might be used as the leading unit to develop novel tubulin polymerization inhibitors as potential anticancer agents. (C) 2021 Elsevier Masson SAS. All rights reserved.
机译:通过去除我们之前报道的化合物3中的5-甲基和6-乙酰基,我们设计了一系列新型的2,7-二芳基-[1,2,4]三唑并[1,5-a]嘧啶衍生物作为潜在的微管蛋白聚合抑制剂。其中,化合物5e对HeLa细胞的抗增殖作用表现出较低的纳摩尔浓度,比铅类似物3高166倍。有趣的是,5e在抑制癌细胞方面比HEK-293(正常人类胚胎肾细胞)表现出显著的选择性。此外,5e通过改变p-cdc2和细胞周期蛋白B1的表达水平,剂量依赖性地将HeLa阻滞在G2/M期,并通过调节裂解的PARP的表达,导致HeLa细胞凋亡。进一步的证据表明,5e有效地抑制了微管蛋白的聚合,其效力是阳性对照CA-4的3倍。此外,分子对接分析表明5e与CA-4在秋水仙碱结合位点上重叠良好。这些研究表明,2,7-二芳基-[1,2,4]三唑并[1,5-a]嘧啶骨架可能被用作开发新型微管蛋白聚合抑制剂作为潜在抗癌剂的主导单元。(c)2021爱思唯尔马松SAS。版权所有。

著录项

  • 来源
  • 作者单位

    Southern Med Univ Sch Pharmaceut Sci Guangdong Prov Key Lab New Drug Screening Guangzhou 510515;

    Southern Med Univ Sch Pharmaceut Sci Guangdong Prov Key Lab New Drug Screening Guangzhou 510515;

    Southern Med Univ Sch Pharmaceut Sci Guangdong Prov Key Lab New Drug Screening Guangzhou 510515;

    Southern Med Univ Sch Pharmaceut Sci Guangdong Prov Key Lab New Drug Screening Guangzhou 510515;

    Southern Med Univ Sch Pharmaceut Sci Guangdong Prov Key Lab New Drug Screening Guangzhou 510515;

    Southern Med Univ Sch Pharmaceut Sci Guangdong Prov Key Lab New Drug Screening Guangzhou 510515;

    Southern Med Univ Sch Pharmaceut Sci Guangdong Prov Key Lab New Drug Screening Guangzhou 510515;

    Southern Med Univ Sch Pharmaceut Sci Guangdong Prov Key Lab New Drug Screening Guangzhou 510515;

    Southern Med Univ Sch Pharmaceut Sci Guangdong Prov Key Lab New Drug Screening Guangzhou 510515;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

    2; 7-Diaryl-1; 2; 4triazolo1; 5-apyrimidine; Anticancer agents; Tubulin inhibitors;

    机译:2.7-二芳基-[1;2;4]三唑并[1;5-a]嘧啶;抗癌药物;微管蛋白抑制剂;

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号